Prolonged complete metabolic response to chemotherapy combined with amivantamab with high grade cutaneous toxicity after osimertinib resistance in an uncommon -mutant lung adenocarcinoma: a case report.

Date publication

avril 2026

Journal

Translational lung cancer research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr PENCREACH Erwan , Dr SCHOTT Roland , Dr SOMME Laura

Tous les auteurs :
Barbe-Richaud JB, Pencreach E, Schott R, Holder E, Somme L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42170257

Résumé

Amivantamab, an epidermal growth factor receptor-MNNG-HOS transforming gene () bispecific antibody with immune cell-directing activity, plus platinum-based polychemotherapy improved survival outcomes in patients with classical mutant metastatic lung cancer previously treated by osimertinib. However, its efficacy in the context of uncommon alterations, particularly the deletion in exon 19, which directly impacts the αC helix, remains uncertain.

Mots clés

Amivantamab, case report, erosive pustular dermatosis (EPD), lung adenocarcinoma, skin toxicity, uncommon epidermal growth factor receptor alteration (uncommon EGFR alteration)

Référence

Transl Lung Cancer Res. 2026 04 30;15(4):110